Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
ZYUS Life Sciences (OTCPK:ZLSCF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
ZYUS Life Sciences 3-Year Book Growth Rate Related Terms
ZLSCF vs SKYI, CBDY, NPHC: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's 3-Year Book Growth Rate falls into.
ZYUS Life Sciences 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 0.00% mean?
ZYUS Life Sciences (ZLSCF) has a 3-Year Book Growth Rate of 0.00% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for ZYUS Life Sciences and its competitors. According to the industry distribution chart, ZYUS Life Sciences ranks #999999 out of 913 companies in the Drug Manufacturers industry.
Is ZYUS Life Sciences' 3-Year Book Growth Rate too high?
ZYUS Life Sciences' current 3-Year Book Growth Rate is 0.00%. Based on the distribution chart, ZYUS Life Sciences ranks #999999 out of 913 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ZYUS Life Sciences has a GF Score™ of 21/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' 3-Year Book Growth Rate compare to SKYI and CBDY?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #999999 out of 913 companies for 3-Year Book Growth Rate. This places ZYUS Life Sciences in the lower half of its industry. The industry median 3-Year Book Growth Rate is 4.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 913 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for ZYUS Life Sciences and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZYUS Life Sciences's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Fairly Valued. The stock's GF Value™ is $0.57, compared to a current price of $0.60 — trading 5.3% above its estimated fair value. The current 3-Year Book Growth Rate is 0.00%. ZYUS Life Sciences' overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current 3-Year Book Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ZYUS Life Sciences (ZLSCF) Overvalued in 2026?
Based on GuruFocus' analysis, ZYUS Life Sciences stock appears to be overvalued.
The current stock price of $0.60 is trading 5.3% above its estimated GF Value™ of $0.57.
GuruFocus considers ZYUS Life Sciences to be Fairly Valued.
Key valuation signals for ZLSCF:
3-Year Book Growth Rate: 0.00%
GF Value™: $0.57 vs. price of $0.60 (5.3% above fair value)
No single metric tells the full story. See the ZLSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
21GF Score
Get the complete analysis for ZLSCF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLSCF has been successfully added to your 
